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Abstract: Derivatives of 5’-amino-adenosine containing methyl 
carboxylate, methyl phosphonate, gem-bisphosphonate, 
bis(methylphosphonate), and -carboxylmethylphosphonate or 
phosphonoacetic moieties were synthesized from a key intermediate 
5’-aminonucleoside. These nucleos(t)ide analogues were envisaged 
as 5’-mono or diphosphate nucleoside mimics. All compounds were 
evaluated for CD73 inhibition in a cell-based assay (MDA-MB-231) 
and towards the purified recombinant protein. Most of them failed to 
reach significant inhibition of AMP hydrolysis by CD73 at 100 µM. 
Among the new compounds, the most interesting ones were 
derivatives 5 and 7, inhibiting recombinant CD73 by 36 and 47% and 
cellular CD73 by 61 and 45% at 100 µM, respectively. Molecular 
modeling allowed to explain partially this lack of activity as predicted 
docking score calculated beforehand were initially encouraging, 
especially for compound 7. 
Introduction 
Ecto‐5’‐nucleotidase CD73 is a glycophosphatidyl-inositol‐
anchored di‐Zn2+ metallo‐phosphatase. It is an important 
enzyme involved in the extracellular catabolism of nucleosides 
and nucleotides working together with the membrane‐bound 
CD39. The latter catalyzes the dephosphorylation of ATP into 
AMP, whereas CD73 dephosphorylates extracellular AMP into 
adenosine and inorganic phosphate. Thus, CD73, as a 
modulator of adenosine production, has been identified as an 
active player and a validated drug target in several diseases, 
such as cancer, autoimmunity, allergy and ischemia–reperfusion 
injury.[1] Numerous studies have shown that the inhibition of 
CD73 activity, both in mice models and in cell cultures, by a 
substrate analogue mimicking ADP (APCP, 5’-methylene-
bisphosphonate adenosine, Figure 1), a monoclonal antibody or 
siRNA, is associated with decreased tumor growth and 
metastasis development, decreased tumor angiogenesis and 
increased activity of immune-modulating therapeutic 
antibodies.[2] In the last few years, exciting progress in the 
development of immunotherapy for the treatment of cancer 
patients have been achieved. Thus, modulation of the immune 
system through a small-molecule approach offers several unique 
advantages (lower cost, facilitated administration…) being 
complementary to and potentially synergistic with immune-
oncology approaches using monoclonal antibodies.[3] This is 
exemplified by the association of two mAbs, one targeting CD73 
(MEDI-9447[4]) and one neutralizing the immune check point PD-
1. However, approaches currently using small molecules to
inhibit CD73 activity are not yet suitable for clinical use. Indeed,
one of the first and well-known small molecule inhibitor (APCP)
has low bioavailability, poor metabolic stability and off-target
related effects presumably associated with chemical instability
and adenosine release.[5] To our knowledge, the most potent
inhibitors of CD73 were described by the team of Prof. Müller
and are structurally related to the APCP skeleton (Figure 1).[6] In
addition, nucleoside analogues incorporating two carboxylate
groups have been  patented.[7] However, no data are available
on the in vivo activity of these two series of compounds.
Therefore, it is still of great interest to design new small-
molecule CD73 inhibitors.
Study of APCP in the active site of CD73 (Figure 2) showed key
structural interactions with the terminal domains in the substrate
binding site.[8] The adenine-base formed hydrophobic π-stacking
interaction between two phenylalanine residues (F417 and
F500), and the diol group of the ribose interacts mainly with
D506. The α-phosphonate group binds with R354 and N245
residues, whereas the β-phosphonate group binds to R395 of C-
terminal domain as well as to N85 and H243 of the N-terminal
domain. In addition, α,β-phosphonate groups chelate the two
Zn2+ ions through the formation of monodentate and bidentate
interactions. Based on these observations and as illustrated in
Figure 1, two types of nucleos(t)ide analogues were designed
using adenosine as scaffold. In particular, 5’-amino-adenosine
was selected as the nitrogen atom allows di-substitution or
formation of additional H-bond interaction. Thus, compounds 1,
4 and 5 incorporate either a carboxylate or a phosphonate group
that may be viewed as equivalent of the phosphate of AMP (the
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natural CD73 substrate). In order to mimic the interaction of the 
α,β-methylene diphosphate group of APCP with R354 and N245, 
a carboxyl oxygen or a phosphoryl oxygen was present in 
derivatives 2, 3, and 6-9, whereas the two oxygen atoms of the 
phosphonate group of bis(methylphosphonate), -carboxyl-
methylphosphonate or phosphonoacetic moieties may mimic the 
chelation of the Zn2+ ions by the -phosphonate of APCP. 
We report herein the synthesis of novel series of N-substituted, 
5’-amino-adenosine derivatives (compounds 1-9, Figure 1) as 
potential AMP or ADP mimics and evaluate their potential as 
CD73 inhibitors in vitro.  
Figure 1. Structures of ADP analogues as potent CD73 inhibitors and studied 
compounds 1-9. 
Figure 2. APCP binding mode within the active site of CD73 (crystal structure 
of the closed form solved by Knapp et al.[8]). A) and B) correspond to two 
orientations. APCP is depicted as pink sticks while connecting residues are 
shown in blue thin sticks and zinc ions as grey spheres. 
Results and Discussion 
Synthesis 
The synthesis of adenosine analogues 1-8 began with 5’-amino-
2’,3’-O-isopropylidene-adenosine 10 (Schemes 1 & 2), which 
can be easily accessed in three steps from commercially 
available adenosine with overall yield about 71%.[9] Synthesis of 
derivatives 1 to 5 (Scheme 1) was envisaged through 
nucleophilic displacement by using methyl bromoacetate[10] or 
diethyl p-toluene sulfonyloxymethylphosphonate (obtained 
before[11]) in presence of a base (either NEt3 or DBU), or 
coupling of diethylphosphonoacetic acid[12] using previously 
described or adapted conditions. Attempts to obtain di-
substituted derivatives, by increasing the number of equivalents 
and/or reaction time, and temperature were unsuccessful. 
Concerning the synthesis of compound 1, the 5’-deoxy-2,3-O-
(isopropylidene)-5’-N-methyl-acetate-5’-aminoadenosine was 
contaminated with triethylammonium salts and directly engaged 
in the next step leading to N-alkylated derivative in 45% yield 
over the two steps. The latter was treated with an equimolar 
amount of 1M NaOH to afford derivative 1. Intermediates 11 and 
13 were isolated in good yields, and removal of the sugar-
protecting group in acidic conditions afforded derivatives 12 and 
14 in 90 and 33% yields, respectively. Deprotection of the 
diethylphosphonoester group for compounds 12 and 14 was 
performed with TMSBr in DMF (Scheme 1). Partially deprotected 
derivatives were eventually isolated such as compounds 3 and 4, 
as well as the desired phosphonic acids 2 and 5, which were 
obtained as sodium salts through ion-exchange on Dowex (Na+ 
form). 
Synthesis of derivative 6 incorporating two phosphonomethyl 
groups and derivatives 7 and 8 incorporating a carboxylate and 
a phosphonate groups was also carried out starting from 5’-
amino-5’-deoxy-2’,3’-O-isopropylidene-adenosine 10 (Scheme 
2). The double Kabachnik-Fields reaction of 10, 
paraformaldehyde, and diethyl phosphite was performed under 
microwave activation and solvent-free conditions.[13] The 
resulting derivative was directly treated in acidic conditions to 
afford compound 15 in 31% yield over the two steps. Then, 
removal of the phosphonic protecting groups was carried out as 
previously described and the desired 5’-N-[bisphosphonomethyl] 
adenosine 6 was obtained quantitatively. 
The -carboxyphosphonate derivative 16 was obtained by using 
the Aza-Pudovick reaction, consisting in the addition of 
diethylphosphite to the in situ generated imine from 10 and 
ethylglyoxylate. This step was also performed under microwave-
assisted and solvent-free conditions as described in the 
literature.[14] Removal of the various protecting groups was 
carried out successively under acidic conditions, affording 
compound 17, and then in presence of TMSBr. During this last 
step, the carboxy(monoethyl)phosphonate ester 7 was 
isolated as major derivative after 31 hours, whereas formation of 
the fully deprotected derivative 8 required 6 days of reaction. In 
both case, -carboxyphosphonate derivatives 7 and 8 were 
isolated as equimolar mixture of the two diastereoisomers. 
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Scheme 1. Synthetic pathways for derivatives 1-5. 
Scheme 2. Synthetic pathways for derivatives 6-8. 
Preparation of (aminomethylene)bisphosphonate derivative 9 
(Scheme 3) was envisaged through a three-component 
condensation involving 10, triethyl orthoformate and diethyl 
phosphite.[15] Despite several attempts, only small amounts of 
the desired compound were obtained and formation of the bis-
adduct corresponding to the reaction of the exocyclic amino 
function of the purine ring was also observed. Thus, the use of a 
fully protected precursor appeared necessary. Protection of the 
amino group in position 6 of the 2’,3’-O-isopropylidene-
adenosine by the 2,5-dimethylpyrrole was selected as it can be 
hydrolyzed in the same conditions as of the ribose protecting 
group. Thus, compound 18 was obtained in 36% yield from 
commercially available adenosine, according to previously 
published procedure.[16] Then azidation in position 5’ was 
performed and compound 19 was subjected to hydrogenation to 
afford the 9-(5-amino-5-deoxy-2,3-O-isopropylidene--D-
ribofuranosyl)-6-(2,5-dimethylpyrrol-1-yl)purine 20. With this fully 
protected intermediate in hand, the method elaborated by E. 
Balint et al.[15] was successfully applied to a nucleosidic 
substrate, affording the gem(bisphosphonate) derivative 21 in 
34% yield. Final steps consisted in removal of the various 
protecting groups as previously reported and lead to the target 
compound 9. 
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Scheme 3. Synthesis of derivative 9. 
In addition to compounds 1-9, we synthesized two analogues, 
such as the -carboxyphosphonate derivative of adenosine as a 
reference (Figure 3, compound 23), to study the impact of the 
nitrogen atom in position 5’ (in comparison to compound 8), and 
the analogue of derivative 6 incorporating Clofarabine (Figure 3, 
compound 24) instead of adenosine to study the influence of the 
nucleosidic residue. Indeed, literature data[7a, 17] tend to show 
that the use of Clofarabine as nucleoside scaffold led to 
increased potency for 5’-ectonucleotidase inhibition (cf. 
Clofarabine PCP, Figure 1). Synthetic pathways of these two 
derivatives are detailed in the SI as compound 23 has already 
been reported in the literature[18] and compound 24 was obtained 
by adapting procedure described in Scheme 2. 
Figure 3. Structures of compounds 23 and 24. 
Inhibitory activity of synthesized compounds 
towards CD73 
The enzymatic activity of CD73 was assessed in presence of all 
adenosine-based derivatives to determine their potential 
inhibitory effect on CD73. Inhibition levels promoted by the 
compounds are shown in Table 1 at 10 or 100 µM with 
recombinant protein, and at 100 µM in the cell based assay. 
Compounds 1-4, 6 and 8 inhibited CD73 activity only weakly at 
high concentration (between 10-44% of inhibition) in both 
conditions. Compounds 5, 7, 9 and 24 exhibited a moderate 
enzymatic inhibition with inhibition values ranging from 45 to 
61% at 100 µM in at least one of the two assays. In contrast, 
derivative 23 was found to promote a strong inhibition on both 
recombinant (76 ± 3%) and cellular (82 ± 4%) CD73 at high 
concentrations, and still significantly (35 ± 4%) at 10 µM (Figure 
4A). As expected, APCP, as well as our previously developed 
inhibitor Clofarabine PCP,[17] used here as positive controls, 
were able to inhibit CD73 activity by more than 90% at high 
concentrations. MTT assays were performed with MDA-MB-231 
cells and studied compounds to estimate cytotoxicity, and 
showed marginal (76% survival for compound 3) or no such 
effect (data not shown). 
Figure 4. A) In vitro enzymatic activity measured in the presence of 
representative compounds: APCP (black bars), derivative 5 (grey), 6 (white), 7 
(green) and 23 (blue). B) IC50 determination for weak compounds 5 (♦), 6 (), 
7 (■), modest 23 (∆) compared to strong inhibitor, APCP (○). 
For the most interesting derivative (23), a detailed inhibition 
curve was obtained in order to determine its IC50 values and 
compared to the ones of weak (5, 6 and 7) or strong (APCP) 
inhibitors (Figure 4B). For all compounds, dose response curves 
followed a regular sigmoidal shape even for derivatives 5-7. IC50 
was determined at 35 ± 6 µM for compound 5, around 35 µM 
and 92 µM for compounds 6 and 7, respectively (with important 
incertitude for compounds 5-7 in this concentration range). In 
contrast, derivative 23 gave a value of 19 ± 6 µM and APCP at 
1.4 ± 1.0 µM. 
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Table 1. Summary of biochemical properties of compounds 1- 9 and 24, and reference compounds (APCP, 23 and Clofarabine PCP). 
Compound # Structure Docking 
Score[a] 
% of inhibition @ 100 
µM (% ±  SEM) 
toward purified 
recombinant-CD73 
% of inhibition @ 10 
µM (% ± SEM)  
toward purified 
recombinant-CD73 
% of inhibition @ 
100 µM (% ±  SEM) 
in cell based assay 
APCP 
147.2 99.5 ± 0.5 81.2 ± 6.7 91 ± 3 
 1 106.4 39.4 ± 5 13.7 ± 3 12 ± 1 
 2 108.8 32.3 ± 2.8 11.9 ± 7.4 27 ± 9 
 3 114.3 19.9 ± 3 18.9 ± 3.5 44 ± 5 
 4 110.7 36 ± 5 10 ± 8.5 29 ± 9 
 5 118.4 36 ± 6 18.5 ± 2 61 ± 8 
 6 132 18 ± 9 13 ± 8 n.d.a. [c]
 7 143.7 46 ± 9 20.2 ± 3 45 ± 6 
 8 
135.3 36.2 ± 5 5.7 ± 4 23 ± 8 
9 136.6 51.9 ± 2 10.5 ± 3 31 ± 7 
23 134.8 76 ± 2.5 35 ± 4 82 ± 4 
 24 132.5 n.a. [b] n.a. [b] 45 ± 9 
Clofarabine PCP 142.8 98.5 ± 1.5 96 ± 2.5 92 ± 4 
[a] Docking score for AMP is 108.5. [b] n.a.: not active. [c] n.d.a: no data available. Data represents Mean ± SEM of 3 independent experiments.
Molecular modeling 
To understand the relatively weak and disappointing inhibition 
observed with most of the 5’-amino-adenosine derivatives, a 
molecular docking study was carried out by using the crystal 
structure of CD73 (4H2I). Best-ranked docking poses (according 
to their docking scores given by the GoldScore fitness function 
which takes into account H-bonding energy, van der Waals 
energy, metal interaction and ligand torsion strain) were 
analyzed for defining the various interactions with CD73 
residues arising upon binding of the compound (Figure 5). 
Binding orientation differed significantly for derivatives 1-4 as 
compared to that of APCP (Figure 5A). Indeed, two major 
features distinguish their binding, first the positioning of the 
nucleobase that is shifted and made weaker π-π interactions 
with the two phenyl residues (F417 and F500) from CD73, and 
consequently the displacement of the ribose weakening its 
interaction with D506 (two H-bonds). Overall, the binding of such 
compounds altered electrostatic interactions between R354 (and 
R395) and 5’-oxygen and those from the α-phosphonate for 
APCP, as it is replaced by a single phosphonate and an amino 
group (preferentially H-bond donor than H-bond acceptor).  
For compound 5, the binding is strongly different to that of APCP 
as seen for compounds 1-4 and again interactions are lost 
between D506 and ribose hydroxyls but also with R354 and 
N245 due to the missing α-phosphonate and between H118 or 
R395 with the missing oxygen of β-phosphonate (Figure 5B). 
This may be explained by the length of the amino-phosphonate 
chain that is shorter for 5 compared to the one of APCP and 
since the electrostatic component is the main driving force to 
connect oxygen near the magnesium ion; this induces a 
translation of the rest of the molecule. The difference in inhibition 
between APCP and the potent CD73 inhibitor (23) may be 
explained by a weakening of electrostatic interactions between 
R354 and oxygen atoms (5’-oxygen, as seen by the larger 
distance of 5.4 Å compared to 3 Å with APCP) and similarly with 
R395 (distance increases from 2.9 to 3.3 Å). In addition to this, a 
slight shift of the ribose moiety is observed inducing an increase 
of the H-bond distance between 2’-oxygen and D506 (from 2.4 
to 2.9 Å) (Figure 5C). A lower activity was observed for 
compound 9 compared to 23 although these two molecules 
differ only by one atom at 5’ position (nitrogen versus oxygen) 
and presented similar DS values. Firstly, docking analysis failed 
to identify important modifications between binding modes for 
these two compounds as they almost superimposed (Figure 6A).  
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Figure 5. Binding prediction by docking for various compounds and 
comparison of interactions mediated with CD73 amino acids. A) Docking 
poses for weak inhibitors such as 2 (light green) and 3 (orange) and showing a 
displacement (black arrow) compared to that of APCP (depicted as yellow 
sticks). B) Large difference observed in binding orientation of compounds 5 
(cyan) and APCP (yellow). C) Comparison between APCP (yellow) and 23 
(pink sticks) highlighting changes of interaction distances between 5’-oxygen 
and R354/R395, and for ribose hydroxyl groups and D506. 
However, a thorough analysis showed that subtle changes 
occurred such as the orientation of the nucleobase between 
both phenyl residues (possibly lowering π-π interactions) and an 
increase of the H-bond formed by the 2’-hydroxyl group and 
D506 (2.9 Å for 23 and 3.2 Å for 9). Most importantly, this single 
atom substitution may reflect either a weakening of the 
interaction with R395 (stronger with an oxygen than a nitrogen 
because of the electronegativity) or a change / break in the H-
bond network formed between water molecules, amino acids 
and compound. Although five water molecules were included 
during the docking, no changes was observed at the vicinity of 
the substituted atom. This loss of activity may also be due to a 
change in the protonation state of H118 during the enzymatic 
reaction (achieved at pH 6.5) leading to a decrease in binding 
affinity of 9 (because of the supplementary hydrogen). 
Comparison of binding poses of compounds 6 and 24 (Figure 
6B), and compound 24 and Clofarabine PCP (Figure 6C), 
highlighted the impact of both the nature of the nucleoside 
(adenosine or Clofarabine) and the bis(methylphosphonate) 
chain on the global positioning of these derivatives. These 
modifications have a strong impact on the orientation of the 
ribose moiety and consequently on the nucleobase positioning 
for compounds 6 and 24. 
Whereas, for methylene bisphosphonate derivatives (APCP and 
Clofarabine PCP) modification of the nucleoside moiety did not 
change the final orientation of the nucleobase, as previously 
described[17]. In Figure 6E, overlay of binding poses of 
compounds 7 and 9 show the differences of interactions 
between the gem-bisphosphonate (7) and -carboxyl-
methylphosphonate (9) with a slight move of the ribose 
weakening the interaction with D506 and R354. More notably, 
this binding pose suggested the loss of a major interaction 
between N245 and the third phosphate oxygen. 
Discussion 
We designed novel AMP or ADP analogues incorporating methyl 
carboxylate, methyl phosphonate, bis(methylphosphonate), 
gem-bisphosphonate, -carboxylmethylphosphonate or - 
phosphonoacetic moieties as potential CD73 inhibitors. The 
replacement of the oxygen atom in the 5’-position of 
endogenous adenosine could allow obtaining di-substituted 
derivatives and may lead to additional interaction(s) in the 
catalytic site of the protein. First of all, the docking scores (DS) 
of the targeted compounds (1-9 and 24) were evaluated and 
compared to the ones of AMP (the natural substrate), APCP, 
Clofarabine PCP and compound 23 as reference compounds 
(Table 1). Most of the derivatives showed a DS higher than AMP 
(108.5), except the methyl carboxylate derivative (1). Based on 
these data, bis(methylphosphonate) (6), gem-bisphosphonate 
(7), and α-carboxylmethylphosphonate (8 and 9) analogues 
attracted our attention as they showed DS values in the same 
range as APCP (147.2) and Clofarabine PCP (142.8). 
Compound 7, including the gem-bisphosphonate moiety, 
seemed to be the most promising one with a DS value of 143.7. 
Thus, this novel series of 5’-aminoadenoside analogues was 
successfully obtained in moderate to good yields and we next 
investigated their ability to interfere with CD73. In all cases, 
replacement of the methylene bisphosphonate group of APCP 
lead to a decreased ability to inhibit CD73. Whereas substitution 
of the oxygen in 5’-position by a nitrogen atom did not seem to 
affect the ligand potency (DS values of 136.6 for compound 9 
and 134.8 for compound 23), it significantly affects the ability to 
inhibit the protein. When, the adenosine moiety was replaced by 
Clofarabine (compounds 6 and 24), it slightly increased the 
potential of the inhibitors but this effect was not able to 
counterbalance the replacement of the nature of the hetero-atom 
in position 5’. Despite our effort in designing original nucleotide 
analogues, the replacement of the P-CH2-P-O5’ pattern, and 
related interaction within the catalytic site of CD73, appears not 
suitable following the here proposed modifications. 
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Figure 6. A) Deciphering the differential activity of compound 9 (blue) and 23 (pink sticks) by analyzing their binding mode. B) Comparison of binding mode of 6 
(salmon sticks) versus 24 (dark green). C) Binding modes of 24 (dark green) and Clofarabine PCP (brown). D) Overlay of binding poses of derivatives 6 (salmon) 
and 8 (white). E) Binding comparison of between compounds 7 (green) and 9 (blue sticks).  
According to the important contribution of the negatively charged 
groups over the final orientation of the inhibitor, it would be 
interesting to increase the distance in between the carboxylate 
and the phosphonate groups, and flexibility in this region may be 
beneficial for zinc ions chelating. In addition, as the location of 
carboxylate and/or phosphonate groups seems to govern the 
correct positioning of the nucleoside moiety, increasing this 
distance may lead to stronger interactions (reduction of the 
bonding length with D506 and hydroxyl groups and improving 
the -stacking between the nucleobase and aromatic residues). 
Conclusions 
Novel series of mono- or di-substituted 5’-aminonucleotide 
analogues including carboxylated or phosphonylated 
substituents, or both, were successfully obtained. All 
synthesized compounds were evaluated for their ability to inhibit 
5’-ectonucleotidase CD73. Among them, phosphonic acids 5 
and 24 showed marginal inhibition of CD73 in the cell based 
assay (45-61% inhibition at 100 µM), as well as derivatives 7 
and 9 with the purified recombinant protein (46-52% inhibition at 
100 µM). We assume that these differences may arise from the 
use of the soluble form of the protein, whereas in the cell-based 
assay the protein is anchored to the membrane. In these two 
cases, our derivatives may access and/or accommodate in a 
different fashion the catalytic site of the protein. In addition, 
molecular modeling showed that the modifications envisaged 
deeply impact the binding modes of the new derivatives in 
comparison to APCP and/or Clofarabine APCP. 
Considering the literature data related to the design of 
nucleos(t)ide analogues as CD73 inhibitors, these results will 
certainly contribute to the establishment of a SAR study and 
further development of novel derivatives. 
Experimental Section 
1H NMR, 13C NMR and 31P spectra were recorded with proton decoupling 
at ambient temperature on the following spectrometers: Bruker Avance III 
A B 
D 
E 
N245 
C 
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(600, 500 or 400 MHz). Chemical shifts () are quoted in parts per million 
(ppm) referenced to the residual solvent peak chloroform (CDCl3) at 7.26 
ppm and 77.16 ppm, dimethyl sulfoxide (DMSO-d6) at 2.50 ppm and 
39.52 ppm, methanol (CD3OD) at 3.41 ppm and 49.00 ppm, and 
deuterium oxide (D2O) at 4.63 ppm relative to tetramethylsilane (TMS). 
For 31P NMR spectra, chemical shifts are reported relative to external 
phosphoric acid (H3PO4). COSY experiments were performed in order to 
confirm proton assignments as well as 2D 1H-13C heteronuclear COSY 
for the attribution of 13C signals. Coupling constants, J, are given in Hertz. 
Mass spectra were recorded on a Micromass Q-Tof mass spectrometer 
using electrospray ionization. The high-resolution mass spectra (HRMS) 
were obtained with a Waters Synapt G2S spectrometer equipped with 
positive electrospray source ionization (ESI), using Leu-enkephalin as an 
internal standard. The capillary voltage was set to 1.2 kV and the 
sampling cone voltage was set to 30 V. Thin layer chromatography was 
performed on pre-coated aluminum sheets of Silica Gel 60 F254 (Merck, 
Art. 5554), visualization of products was accomplished by UV 
absorbance followed by spraying with Hanes molybdate reagent. Column 
chromatography was carried out on Silica Gel 60 (Merck, Art. 9385). All 
moisture sensitive reactions were carried out in anhydrous conditions 
under argon atmosphere using oven-dried glassware. Solvents were 
dried and distilled prior to use and solids were dried over P2O5 under 
reduced pressure at room temperature. 
General Procedure (A) for removal of acid labile sugar protecting 
groups. The protected derivative was dissolved in TFA-H2O (ratio 1/1, 30 
mL/mmol) at room temperature and stirred until TLC indicated completion 
of the reaction. Then, the solvents were evaporated and the crude was 
co-evaporated with EtOH under reduced pressure. The crude material 
was purified by flash chromatography on silica gel to afford the desired 
product. 
General Procedure (B) for diethyl phosphonate removal. The protected 
phosphonate (1 eq.) was dissolved in anhydrous DMF (20 mL/mmol) and 
trimethylsilyl bromide (15 eq.) was added dropwise at 0°C. The reaction 
mixture was stirred at room temperature until completion of the reaction 
was indicated by TLC (iPrOH/NH4OH/H2O, 7/2/1, v/v/v). Then, the 
reaction was stopped by adding triethylammonium bicarbonate buffer 
(TEAB 1 M, pH 7) and concentrated to dryness under high vacuum. 
Column chromatography of the crude materials on reverse phase 
(gradient: H2O to MeOH 100%) gave the expected phosphonic acid (as 
triethylammonium salt), which was passed through a Dowex Na+ ion 
exchange column, the desired fractions were collected and freeze dried 
leading to the title compound as sodium salt. 
5’-Amino-5’-deoxy-2’,3’-O-(isopropylidene)adenosine (10) was 
obtained from commercially available adenosine in 3 steps with 71% 
overall yield according to previously published procedures. [9] 
Characterizations (1H, 13C and MS) were in agreement with the literature. 
Rf (CH2Cl2/MeOH 9/1) 0.04. 1H NMR (300 MHz, CDCl3): δ 8.31 (s, 1H, H-
2), 7.91 (s, 1H, H-8), 6.11 (s, 2H, NH2), 6.02 (d, J = 3.0 Hz, 1H, H-1’), 
5.46 (dd, J = 6.5, 3.0 Hz, 1H, H-2’), 5.01 (dd, J = 6.5, 3.5 Hz, 1H, H-3’), 
4.24 (dd, J = 9.3, 4.5 Hz, 1H, H-4’), 2.99 (qd, J = 13.4, 5.2 Hz, 2H, H-5’), 
1.72 (s, 2H, CH2-NH2), 1.60 (s, 3H, CH3), 1.37 (s, 3H, CH3). 13C NMR (75 
MHz, CDCl3): δ 155.9 (C-6), 153.3 (C-2), 149.5 (C-4), 140.0 (C-8), 120.5 
(C-5), 114.7 (C(CH3)2), 90.8 (C-1’), 87.7 (C-4’), 83.8 (C-2’), 82.0 (C-3’), 
44.0 (C-5’), 27.4 (CH3), 25.5 (CH3). Q-TOF MS E+: m/z 307.15 (M+H)+. 
HRMS Q-TOF MS E+: Calculated for C13H19N6O3 [M+H]+ 307.1519; found 
307.1521. 
5’-N-acetate-5’-deoxyadenosine (1) To a suspension of compound 10 
(535 mg, 1.61 mmol) in anhydrous MeOH (32 mL) and under argon 
atmosphere was added freshly distilled triethylamine (566 µL, 2.5 eq.). 
Methyl bromoacetate (312 µL, 2.05 eq.) was then dropwise added over a 
period of 2 h and the reaction mixture was refluxed overnight before 
concentration under reduced pressure. Purification by flash 
chromatography on silica gel (CH2Cl2/MeOH, 19/1 to 9/1) afforded the 
alkylated intermediate as white solid (705 mg containing 20% of 
triethylammonium salts). This last was directly used in the next step 
without further purification. Rf (CH2Cl2/MeOH 9/1) 0.41. Q-TOF MS E+: 
m/z 379.17 (M+H)+. HRMS Q-TOF MS E+: Calculated for C16H23N6O5 
([M+H]+ 379.1730; found: 379.1728. This derivative (200 mg, 0.44 mmol) 
was treated following general procedure A. Purification was achieved by 
flash chromatography on silica gel (EtOAc/MeOH, 100/0 to 50/50) to give 
the deprotected intermediate (as a white solid, 246 mg, 45% for two 
steps) which was engaged in the saponification step. Rf (EtOAc/MeOH 
1/4) 0.40. Q-TOF MS E+: m/z 339.14 (M+H)+. Q-TOF MS E-: m/z 337.10 
(M-H)-. HRMS Q-TOF MS E+: Calculated for C13H19N6O5 [M+H]+ 
339.1417; found: 339.1418. UV (EtOH abs) λmax = 259 nm (εmax = 9710). 
Thus, methyl ester derivative (194 mg, 0.58 mmol) was dissolved in 
NaOH 1M solution and stirred at room temperature for 2 h. The volatiles 
were removed under reduced pressure and the crude was purified by 
flash chromatography on silica gel (EtOAc/MeOH, 1/2 to 0/100) to afford 
compound 1 as a white solid (118 mg, 60%). Rf (EtOAc/MeOH 1/9) 0.05. 
1H NMR (600 MHz, D2O): δ 8.31 (s, 1H, H-2), 8.20 (s, 1H, H-8), 6.08 (d, J 
= 5.5 Hz, 1H, H-1’), H-2’ (signal in D2O peak), 4.39 – 4.35 (m, 2H, H-3’, 
H-4’), 3.45 – 3.38 (m, 2H, CH2-CO), 3.17 (d, J = 5.6 Hz, 2H, H-5’). 13C 
NMR (151 MHz, D2O): δ 176.5 (C=O), 155.5 (C-6), 152.8 (C-2), 148.7 
(C-4), 140.3 (C-8), 118.9 (C-5), 88.1 (C-1’), 82.2 (C-4’), 73.5 (C-2’), 71.5 
(C-3’), 51.3 (CH2-CO), 49.9 (C-5’). Q-TOF MS E+: m/z 347.11 (M+H)+. 
HRMS Q-TOF MS E+: Calculated for C12H17N6O5 [M-Na+2H]+ 325.1260;
found: 325.1261.
5’-Deoxy-5’-N-[(diethyl-phosphono)acetyl]-2’,3’-O-isopropylidene-
adenosine (11)[12] Diethyl phosphonoacetic acid (321 µL, 2 eq.) was 
slowly added, at room temperature and under an argon atmosphere, to a 
solution of compound 10 (306 mg, 1 mmol), DCC (495 mg, 2.4 eq.) and 
4-DMAP (12 mg, 0.1 eq.) in anhydrous DMF (12 ml). After 20 h, the 
reaction mixture was filtered and the filtrate was evaporated under
reduced pressure. The resulting oil was then co-evaporated 3 times with
EtOH (10 mL) before dissolution with CH2Cl2. The organic layer was
washed with H2O (twice), dried (MgSO4), filtered and concentrated to 
dryness. The resulting oil was purified by silica gel column 
chromatography (CH2Cl2/MeOH, 9/1) to give compound 11 as a yellow 
foam (233 mg, 72%). Rf (CH2Cl2/MeOH 9/1) 0.33. 1H NMR (300 MHz,
CDCl3): δ 8.39 (brs, 1H, NH), 8.37 (s, 1H, H-2), 7.93 (s, 1H, H-8), 6.00 
(brs, 2H, NH2), 5.87 (d, J = 4.5 Hz, 1H, H-1’), 5.37 (dd, J = 6.2, 4.5 Hz,
1H, H-2’), 4.86 (dd, J = 6.3, 2.3 Hz, 1H, H-3’), 4.46 (dd, J = 5.9, 3.3 Hz,
1H, H-4’), 4.20 – 4.01 (m, 5H, O-CH2 and H-5’), 3.38 – 3.33 (m, 1H, H-5’),
2.97 (dd, J = 21.4, 4.7 Hz, 2H, CH2-P), 1.60 (s, 3H, CH3), 1.35 (s, 3H,
CH3), 1.33 – 1.27 (m, 6H, O-CH2-CH3). 13C NMR (75 MHz, CDCl3): δ 
165.4 (d, J = 4.9 Hz, C=O), 155.8 (C-6), 152.8 (C-2), 148.7 (C-4), 140.3 
(C-8), 119.8 (C-5), 114.9 (C(CH3)2), 91.1 (C-1’), 83.8 (C-4’), 82.9 (C-2’),
81.5 (C-3’), 63.1 (d, J = 11.2 Hz, O-CH2-CH3), 41.2 (C-5’), 35.2 (d, J = 
134.1 Hz, CH2-P), 27.0 (C(CH3)2), 25.0 (C(CH3)2), 15.98 (d, J = 6.1 Hz,
O-CH2-CH3). 31P NMR (121 MHz, CDCl3): δ 22.1. Q-TOF MS E+: m/z
485.19 (M+H)+. HRMS Q-TOF MS E+: Calculated for C19H29N6O7P 
[M+H]+ 485.1914; found: 485.1923. 
5’-Deoxy-5’-N-[(diethyl-phosphono)acetyl]adenosine (12)[12] The title 
compound was obtained as a white solid (350 mg, 90%) from compound 
11 (424 mg, 0.876 mmol) using general procedure A. Purification was 
achieved by flash chromatography on silica gel (CH2Cl2/MeOH, 9/1. Rf 
(CH2Cl2/MeOH 9/1) 0.08. 1H NMR (300 MHz, DMSO-d6): δ 8.39 (s, 1H, 
H-2), 8.19 (s, 1H, H-8), 7.40 (brs, 2H, NH2), 5.86 (d, J = 6.3 Hz, 1H, H-1’),
5.43 (brs, 1H, OH), 5.28 (brs, 1H, OH), 4.68 (t, J = 5.7 Hz 1H, H-2’), 4.07 
– 3.93 (m, 6H, H-3’, H-4’ and O-CH2-CH3), H-5’ (signal in H2O peak.),
2.91 (d, J = 21.4 Hz, 2H, CH2-P), 1.21 (t, J = 7.1 Hz, 6H, CH3). 13C NMR
(75 MHz, DMSO-d6): δ 164.3 (C=O), 156.0 (C-6), 152.3 (C-2), 149.3 (C-
4), 140.4 (C-8), 119.4 (C-5), 87.6 (C-1’), 83.5 (C-4’), 72.7 (C-2’), 71.1 (C-
3’), 61.7 (d, J = 6.1 Hz, O-CH2-CH3), 41.3 (C-5’), 34.6 (d, J = 132.3 Hz,
CH2-P), 16.2 (d, J = 5.8 Hz, CH3). 31P NMR (121 MHz, DMSO-d6): δ 22.8.
Q-TOF MS E+: m/z 445.16 (M+H)+.
5’-Deoxy-5’-N-(phosphono-acetyl)adenosine (disodium salts) (2)[12] 
The title compound was obtained as a white solid (17 mg, 7%) from 
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compound 12 (287 mg, 0.646 mmol) using general procedure B. 
Purification was achieved by flash chromatography on reverse phase 
(H2O/MeOH, 100/0 to 50/50). Rf (iPrOH/H2O/NH4OH, 6/3/1) 0.39. 1H 
NMR (400 MHz, D2O): δ 8.31 (s, 1H, H-2), 8.19 (s, 1H, H-8), 6.01 (d, J = 
5.6 Hz, 1H, H-1’), H-2’ signal in D2O peak, 4.35 (t, J = 4.8 Hz, 1H, H-2’), 
4.28 (q, J = 4.8 Hz, 1H, H-4’), 3.65 and 3.56 (ABX, J = 14.5, 5.3, 4.8 Hz, 
2H, H-5’), 2.62 (d, J = 19.2 Hz, 2H, CH2-P). 13C NMR (101 MHz, D2O): δ 
172.4 (d, J = 4.4 Hz, C=O), 155.4 (C-6), 152.7 (C-2), 148.7 (C-4), 140.2 
(C-8), 118.8 (C-5), 87.4 (C-1’), 83.2 (C-4’), 73.2 (C-2’), 70.9 (C-3’), 40.9 
(C-5’), 38.4 (d, J = 115.1 Hz, CH2-P). 31P NMR (162 MHz, D2O): δ 12.45. 
Q-TOF MS E+: m/z 389.10 (M+H)+. HRMS Q-TOF MS E+: for Calculated
C12H18N6O7P [M+H]+ 389.0975; found: 389.0975. UV (EtOH abs) λmax = 
261 nm (εmax = 12300).
5’-Deoxy-5’-N-(ethyl-phosphono-acetyl)adenosine (monosodium 
salt) (3) Compound 3 was obtained as a white solid (60 mg, 20%) from 
compound 12 (350 mg, 0.790 mmol) using general procedure B. 
Purification was achieved by flash chromatography on reverse phase 
(H2O/MeOH, 100/0 to 50/50). Rf (iPrOH/H2O/NH4OH, 6/3/1) 0.59. 1H 
NMR (400 MHz, D2O): δ 8.31 (s, 1H, H-2), 8.25 (s, 1H, H-8), 6.01 (d, J = 
5.6 Hz, 1H, H-1’), 4.84 – 4.81 (m, 1H, H-2’), 4.35 – 4.26 (m, 2H, H-3’ and 
H-4’), 3.92 – 3.83 (m, 2H, O-CH2-CH3), 3.70 and 3.51 (ABX, J = 15.5, 5.2,
3.7 Hz, 2H, H-5’), 2.72 (d, J = 20.3 Hz, 2H, CH2-P), 1.15 (t, J = 7.1 Hz,
3H, CH3).13C NMR (101 MHz, D2O): δ 170.3 (d, J = 5.7 Hz, C=O), 155.6 
(C-6), 152.9 (C-2), 148.8 (C-4), 140.5 (C-8), 119.0 (C-5), 87.7 (C-1’),
83.3 (C-4’), 73.1 (C-2’), 70.9 (C-3’), 61.3 (d, J = 5.9 Hz, O-CH2-CH3),
40.9 (C-5’), 36.4 (d, J = 122.0 Hz, CH2-P), 15.83 (d, J = 6.2 Hz, CH3). 31P 
NMR (162 MHz, D2O): δ 16.0. Q-TOF MS E+: m/z 439.11 (M+H)+. Q-TOF 
MS E-: m/z 415.11 (M-Na)-. HRMS Q-TOF MS E+: Calculated for 
C14H21N6O7NaP [M+H]+ 439.1107; found: 439.1108. UV (EtOH abs) 
λmax = 259 nm (εmax = 13900).
5’-Deoxy-5’-N-[(diethyl-phosphono)methyl]-2’,3’-O-isopropylidene-
adenosine (13) A solution of compound 10 (408 mg, 1.2 mmol) in 
anhydrous THF (4 mL) was added, at room temperature, to a mixture of 
(diethoxyphosphoryl)methyl 4-methylbenzenesulfonate (322 mg, 1.0 
mmol) and DBU (152 µl, 1.0 mmol) under an argon atmosphere. The 
reaction mixture was stirred at 50°C for 4 days before concentration 
under reduced pressure. The crude was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 9/1) to give 13 as a white 
solid (232 mg, 51%). Rf (CH2Cl2/MeOH 9/1) 0.40. 1H NMR (400 MHz, 
CDCl3): δ 8.35 (s, 1H, H-2), 7.92 (s, 1H, H-8), 6.00 (d, J = 3.0 Hz, 1H, H-
1’), 5.77 (s, 2H, NH2), 5.42 (dd, J = 6.3, 3.1 Hz, 1H, H-2’), 5.02 (dd, J = 
6.3, 3.3 Hz, 1H, H-3’), 4.35 – 4.33 (m, 1H, H-4’), 4.16 – 4.07 (m, 4H, O-
CH2-CH3), 3.07 – 2.93 (m, 4H, H-5’ + CH2-P), 1.60 (s, 3H, CH3), 1.37 (s, 
3H, CH3), 1.35 – 1.27 (m, 6H, O-CH2-CH3). 13C NMR (101 MHz, CDCl3): 
δ 155.7 (C-6), 153.4 (C-2), 149.6 (C-4), 140.0 (C-8), 120.5 (C-5), 114.7 
(C(CH3)2), 90.9 (C-1’), 85.6 (C-4’), 83.6 (C-2’), 82.3 (C-3’), 62.2 (d, J = 
6.6 Hz, O-CH2-CH3), 52.5 (d, J = 13.0 Hz, C-5’), 45.3 (d, J = 154.5 Hz, 
CH2-P), 27.4 (CH3), 25.5 (CH3), 16.6 (d, J = 5.7 Hz, O-CH2-CH3). 31P 
NMR (162 MHz, CDCl3): δ 25.7. Q-TOF MS E+: m/z 457.20 (M+H)+. 
HRMS Q-TOF MS E+: Calculated for C18H30N6O6P [M+H]+ 457.1964; 
found: 457.1965. 
5’-Deoxy-5’-N-[(diethyl-phosphono)methyl]adenosine (14) The title 
compound was obtained as a white solid (60 mg, 33%) from compound 
13 (200 mg, 0.438 mmol) using general procedure A. Purification was 
achieved by flash chromatography on reverse phase (H2O/MeOH, 100/0 
to 50/50). Rf (CH2Cl2/MeOH 9/1) 0.06. 1H NMR (300 MHz, D2O): δ 8.27 (s, 
1H, H-2), 8.25 (s, 1H, H-8), 6.07 (d, J = 5.4 Hz, 1H, H-1’), 4.86 – 4.82 (m, 
1H, H-2’), 4.47 – 4.41 (m, 2H, H-3’and H-4‘), 4.19 – 4.06 (m, 4H, O-CH2-
CH3), 3.55 (d, J = 13.5 Hz, 2H, H-5’), 3.49 (d, J = 5.8 Hz, 2H, CH2-P), 
1.23 (t, J = 6.9 Hz, 3H, CH3), 1.19 (t, J = 6.8 Hz, 3H, CH3). 13C NMR (75 
MHz, D2O): δ 155.3 (C-6), 152.3 (C-2), 148.4 (C-4), 141.0 (C-8), 119.3 
(C-5), 89.2 (C-1’), 80.1 (C-4’), 73.0 (C-2’), 71.6 (C-3’), 64.6 (d, J = 6.5 Hz, 
O-CH2-CH3), 50.3 (d, J = 9.6 Hz, C-5’), 41.2 (d, J = 153.1 Hz, CH2-P),
15.5 – 15.3 (m, CH3). 31P NMR (121 MHz, D2O): δ 20.6. Q-TOF MS E+: 
m/z 417.17 (M+H)+. HRMS Q-TOF MS E+: Calculated for C15H26N6O6P 
[M+H]+ 417.1651; found: 417.1651. 
5’-Deoxy-5’-N-[(ethyl-phosphono)methyl]adenosine (monosodium 
salt) (4) The title compound was obtained as a white solid (40 mg, 29%) 
from compound 14 (140 mg, 0.336 mmol) using general procedure B. 
Purification was achieved by flash chromatography on reverse phase 
(H2O/MeOH, 100/0 to 50/50). Rf (iPrOH/NH4OH/H2O, 7/2/1) 0.43. 1H 
NMR (400 MHz, D2O): δ 8.30 (s, 1H, H-2), 8.24 (s, 1H, H-8), 6.07 (d, J = 
5.6 Hz, 1H, H-1’), 4.85 – 4.82 (m, 1H, H-2’), 4.39 – 4.35 (m, 2H, H-3’, H-
4’), 3.89 – 3.84 (m, 2H, O-CH2-CH3), 3.26 – 3.24 (m, 2H, H-5’), 3.05 – 
2.93 (m, 2H, CH2-P), 1.13 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (101 MHz, 
D2O): δ 155.6 (C-6), 152.9 (C-2), 148.7 (C-4), 140.4 (C-8), 119.0 (C-5), 
88.2 (C-1’), 81.9 (C-4’), 73.2 (C-2’), 71.6 (C-3’), 60.9 (d, J = 5.8 Hz, O-
CH2-CH3), 51.3 (d, J = 10.2 Hz, C-5’), 44.0 (d, J = 142.9 Hz, CH2-P), 15.8 
(d, J = 5.9 Hz, CH3). 31P NMR (162 MHz, D2O): δ 17.7. Q-TOF MS E+: 
m/z 411.12 (M+H)+. Q-TOF MS E-: m/z 387.12 (M-Na)+. HRMS Q-TOF 
MS E+: Calculated for C13H21N6O6NaP [M+H]+ 411.1158; found: 
411.1161. UV (EtOH abs) λmax = 259 nm (εmax = 15800). 
5’-Deoxy-5’-N-phosphonomethyladenosine (disodium salt) (5) The 
title compound was obtained as a white solid (29 mg, 17% over the 2 
steps) from compound 13 (182 mg, 0.4 mmol) using general procedure 
B. The residue was purified on reverse phase (H2O/MeOH: 100/0) to give 
the intermediate deprotected phosphonate (37 mg). This last was
subsequently treated following procedure A. Purification on reverse
phase (H2O/MeOH: 100/0) followed by an ion exchange on DOWEX 
50WX2 (Na+ form). 1H NMR (500 MHz, D2O): δ 8.27 (s, 1H, H-8), 8.23 (s, 
1H, H-2), 6.07 (d, J = 5.4 Hz, 1H, H-1’), H-2’ signal in D2O peak, 4.48 – 
4.45 (m, 1H, H-4’), 4.42 (t, J = 4.8 Hz, 1H, H-3’), 3.60 – 3.52 (m, 2H, H-
5’), 3.00 (d, J = 11.6 Hz, 2H, CH2P). 13C NMR (126 MHz, D2O): δ 155.5 
(C-6), 152.9 (C-2), 148.6 (C-4), 140.5 (C-8), 119.0 (C-5), 88.6 (C-1’),
80.0 (C-4’), 73.2 (C-2’), 71.4 (C-3’), 50.8 (C-5’), 46.6 (d, J = 128.9 Hz,
CH2-P). 31P NMR (162 MHz, D2O): δ 7.34. Q-TOF MS E+: m/z 405.07
(M+H) +. HRMS Q-TOF MS E+: calculated for C11H16N6O6PNa2 [M+H] +
405.0664 found; 405.0663.
5’-Deoxy-5’-N-[(tetraethyl-bisphosphono)methyl]adenosine (15) 
Compound 10 (302.4 mg, 0.98 mmol), paraformaldehyde (62.9 mg, 2 
eq.) and diethylphosphite (0.26 mL, 2 eq.) were sealed in a microwave 
reactor. Under stirring, microwave irradiations were applied for 1h at 
100°C with a power of 850 Watts. The crude mixture was purified on 
silica gel flash chromatography (CH2Cl2/MeOH: 90/10) to afford protected 
intermediate (300 mg, 0.5 mmol). This latter was treated following 
procedure A. The residue was co-evaporated with EtOH and gave, after 
purification on reverse phase (H2O/MeOH: 100/0 to 0/100) and freeze-
drying, the desired compound 15 as a white solid (172.3 mg, 31%). Rf 
(iPrOH/NH4OH/H2O, 7/1/2) 0.81. 1H NMR (500 MHz, CDCl3): δ 8.25 (s, 
1H, H-2), 8.11 (s, 1H, H-8), 6.27 (br s, 2H, NH2), 6.01 (d, J = 3.9 Hz, 1H, 
H-1’), 4.65 – 4.63 (m, 1H, H-2’), 4.55 – 4.53 (m, 1H, H-3’), 4.21 – 4.18 (m,
1H, H-4’), 4.12 – 4.08 (m, 8H, O-CH2-CH3), 3.26 – 3.11 (m, 6H, CH2-P + 
H-5’), 1.30 – 1.27 (m, 12H, O-CH2-CH3).13C NMR (126 MHz, CDCl3): δ 
155.6 (C-6), 152.9 (C-2), 149.6 (C-4), 139.6 (C-8) 119.8 (C-5), 89.2 (C-
1’), 83.3 (C-4’), 74.5 (C-2’), 71.2 (C-3’), 62.5 (O-CH2-CH3), 57.8 (C-5’),
52.4 (d, J = 7.5 Hz, CH2-P), 51.1 (d, J = 7.5 Hz, CH2-P), 16.6 (O-CH2-
CH3).31P NMR (202 MHz, CDCl3): δ 24.6. Q-TOF MS E+: m/z 567.21 
(M+H)+. HRMS Q-TOF MS E+: calculated for C20H37N6O9P2 [M+H]+
567.2097; found 567.2103.
5’-Deoxy-5’-N-[(bisphosphono)methyl]adenosine (tetra sodium salt) 
(6) The title compound was obtained as a white solid (158 mg,
quantitative yield) from compound 15 (165 mg, 0.3 mmol) using general 
procedure B. After stirred at room temperature for 24 h, trimethylsilyl
bromide (200 µL, 5 eq.) was added and the mixture stirred at room
temperature for 5 h. Purification by reverse-phase column 
chromatography with H2O followed by ion exchange on DOWEX 50WX2 
(Na+ form) provided compound 6 as a white solid (158 mg, quantitative 
yield).  1H NMR (500 MHz, D2O): δ 8.38 (s, 1H, H-2), 8.30 (s, 1H, H-8), 
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6.14 (d, J = 5.3 Hz, 1H, H-1’), H-2’ signal in D2O peak, 4.67 – 4.63 (m, 
1H, H-4’), 4.43 – 4.41 (m, 1H, H-3’), 4.06 – 3.84 (m, 2H, H-5’), 3.61 – 
3.47 (m, 4H, CH2-P). 13C NMR (126 MHz, D2O): δ 155.4 (C-6), 152.6 (C-
2), 148.7 (C-4), 140.7 (C-8), 119.2 (C-5), 88.7 (C-1’), 78.7 (C-4’), 73.1 (C-
2’), 71.6 (C-3’), 58.1 (C-5’), 52.6 (CH2P), 51.6 (CH2P). 31P NMR (121 
MHz, D2O): δ 7.9. Q-TOF MS E-: m/z 475.05 (M-H)-. HRMS Q-TOF MS 
E-: calculated for C12H18N6O9NaP2 [M-H]- 475.0508; found 475.0511. 
5’-Deoxy-5’-N-[(diethoxyphosphorylethylacetate)]-2’,3’-O-isopropyl-
idene-adenosine (16) To a stirred solution of 10 (419.4 mg, 1.37 mmol) 
in freshly distilled dichloromethane (7 mL) was added MgSO4 (300 mg, 5 
eq.) and ethylglyoxylate (50% solution (wt.) in toluene, 272 µL, 1.2 eq.) 
under an argon atmosphere. After stirring at room temperature for 3 h, 
the mixture was filtered and concentrated in vacuum to afford the 
intermediate imine. It was transferred in a microwave reactor and diethyl 
phosphite (700 µL, 4 eq.) was added, then the mixture was irradiated by 
microwave for 6 h at 100°C with a power of 850 Watts. Purification by 
flash chromatography on silica gel (CH2Cl2/MeOH: 90/10) afforded 1/1 
mixture of diastereomers 16 as a white solid (375 mg, 53%). Rf 
(CH2Cl2/MeOH, 9/1) 0.48. 1H NMR (500 MHz, CDCl3): δ 8.39 (s, 1H, H-2, 
dia1 or dia2), 8.36 (s, 1H, H-2, dia1 or dia2), 8.06 (s, 1H, H-8, dia1 or 
dia2), 7.95 (s, 1H, H-8, dia1 or dia2), 6.06 (d, J = 2.9 Hz, 1H, H-1’, dia1), 
6.03 (d, J = 3.2 Hz, 1H, H-1’, dia2), 5.74 (br s, 4H, NH2, dia1 + dia2), 5.42 
(dd, J = 6.5, 3.0 Hz, 1H, H-2’, dia1), 5.39 (dd, J = 6.4, 3.2 Hz, 1H, H-2’, 
dia2), 5.07 (dd, J = 6.4, 3.2 Hz, 1H, H-3’, dia2), 5.02 (dd, J = 6.5, 3.4 Hz, 
1H, H-3’, dia1), 4.37 – 4.32 (m, 2H, H-4’, dia1 + dia2), 4.24 – 4.11 (m, 
12H, O-CH2-CH3, dia1 + dia2), 3.77 (s, 1H, CHP, dia1 or dia2), 3.72 (s, 
1H, CHP, dia1 or dia2), 3.10 (dd, J = 4.0, 12.7 Hz, 1H, H-5’, dia2), 2.98-
2.86 (m, 2H, H-5’, dia1 + dia2), 2.79 (dd, J = 3.8, 12.7 Hz, 1H, H-5’ dia2), 
1.61 (s, 6H, CH3 dia1 + dia2), 1.38 (s, 6H, CH3, dia1 + dia2), 1.33 – 1.29 
(m, 12H, O-CH2-CH3, dia1 + dia2), 1.24 – 1.21 (m, 6H, O-CH2-CH3, dia1 
+ dia2). 13C NMR (126 MHz, CDCl3): δ 169.2 (CO, dia1 or dia2), 169.1 
(CO, dia1 or dia2),  155.6 (C-6, dia1 + dia2), 153.5 (C-2, dia1 or dia2), 
153.3(C-2, dia1 or dia2), 149.6 (C-4, dia1 + dia2), 140.1 (C-8, dia1),
139.9 (C-8, dia2), 120.5 (C-5, dia1 or dia2), 120.4 (C-5, dia1 or dia2),
114.8 (C(CH3)2, dia1), 114.7 (C(CH3)2, dia2), 91.0 (C-1’, dia2), 90.4 (C-1’, 
dia1), 86.3 (C-4’, dia1), 85.9 (C-4’, dia2), 83.9 (C-2’, dia1), 83.7 (C-2’,
dia2), 82.3 (C-3’, dia1 + dia2), 63.6 (O-CH2-CH3, dia1 + dia2), 63.5 –
63.4 (O-CH2-CH3, dia1 + dia2), 61.9 (O-CH2-CH3, dia1 + dia2), 61.4 – 
61.3 (CHP, dia1 or dia2), 60.2 (CHP, dia1 or dia2), 50.8 – 50.6 (C-5’,
dia1 + dia2), 27.5 (CH3 , dia1 + dia2), 27.4 (CH3, dia1 + dia2),  16.6 – 
16.5 (P-O-CH2-CH3, dia1 + dia2), 14.2 (C-O-CH2-CH3, dia1 + dia2). 31P 
NMR (202 MHz, CDCl3): δ 17.6 (dia1 or dia2), 17.5 (dia1 or dia2). Q-TOF
MS E+: m/z 529.22 (M+H)+. HRMS Q-TOF MS E+: calculated for 
C21H34N6O8P [M+H]+ 529.2176; found 529.2177.
5’-Deoxy-5’-N-[(diethoxyphosphorylethylacetate)]adenosine (17) The 
title compound was obtained as a white solid (330.2 mg, 98%) from 
compound 16 (365.2 mg, 0.69 mmol) using general procedure A. 
Purification was carried by flash chromatography on silica gel 
(CH2Cl2/MeOH, 9/1)). Rf (CH2Cl2//MeOH, 9/1) 0.32. 1H NMR (300 MHz, 
CD3OD): δ 8.36 – 8.26 (m, 4H, H-2 & H-8, dia1 + dia2), 5.98 (d, J = 5.5 
Hz, 1H, H-1’, dia1), 5.94 (d, J = 5.9 Hz, 1H, H-1’, dia2), H-2’ dia2 signal in 
H2O peak), 4.80 – 4.77 (m, 1H, H-2’, dia1), 4.38 (dd, J = 5.3, 3.5 Hz, 1H, 
H-3’, dia2), 4.26 – 4.10 (m, 15H, O-CH2-CH3, H-3’ dia1 and H-4’ dia1 + 
dia2), 3.15 (dd, J = 12.8, 3.1 Hz, 1H, H-5’ dia2), 3.03 – 3.00 (m, 2H, H-5’, 
dia1 + dia2), 2.83 (dd, J = 12.8, 4.9 Hz, 1H, H-5’, dia2), 1.34 – 1.20 (m, 
18H, O-CH2-CH3, dia1 + dia2). 13C NMR (126 MHz, CD3OD): δ 170.4 
(CO, dia1 + dia2), 156.6 (C-6, dia1 or dia2), 156.4 (C-6, dia1 or dia2),
152.8 (C-2, dia1), 152.7 (C-2, dia2), 150.6 (C-4, dia1), 150.5 (C-4, dia2),
142.5 (C-8, dia2), 142.1 (C-8, dia1), 120.8 (C-5, dia2), 120.7 (C-5, dia1),
90.8 (C-1’, dia2), 90.4 (C-1’, dia1), 86.3 (C-4’, dia2), 85.9 (C-4’, dia1),
75.0 (C-2’, dia1), 74.6 (C-2’, dia2), 73.0 (C-3’, dia1), 72.9 (C-3’, dia2),
65.3 – 64.8 (m, O-CH2-CH3, dia1 + dia2), 63.0 (CHP, dia1 + dia2), 51.9 – 
51.4 (C-5’, dia1 + dia2), 16.8 – 14.4 (m, C(O)CH2-CH3 and P(O)-CH2-
CH3, dia1 + dia2). 31P NMR (202 MHz, CD3OD): δ 18.4 (dia1 or dia2),
18.3 (dia1 or dia2). Q-TOF MS E+: m/z 489.19 (M+H)+. HRMS Q-TOF
MS E+: calculated for C18H30N6O8P [M+H]+ 489.1863; found 489.1866.
5’-Deoxy-5’-N-[(ethoxyphosphorylacetate)]adenosine (disodium 
salt) (7) The title compound was obtained as a white solid (71.6 mg, 
78%) from compound 17 (94.5 mg, 0.19 mmol) using general procedure 
B. Purification by reverse-phase column chromatography with 
H2O/MeOH (100/0 to 0/100) afford the desired intermediate as a 
triethylammonium salt. This last was treated with NaOH solution (1M in
H2O, 300 µL, 1.5 eq.) and the mixture was stirred at room temperature 
overnight. The mixture was neutralized with a saturated aqueous solution 
of NH4Cl. After freeze-drying, purification by reverse phase column 
chromatography with H2O/MeOH (100/0 to 0/100) and ion exchange on
DOWEX 50WX2 (Na+ form) afforded the desired mixture of
diastereomers 7. Rf (iPrOH/NH4OH/H2O, 7/1/2) 0.62. 1H NMR (500 MHz,
D2O): δ 8.33 – 8.29 (m, 4H, H-2 and H-8, dia1 + dia2), 6.11 – 6.09 (m,
2H, H-1’, dia1 + dia2), H-2’ dia1 + dia2 signal in D2O peak, 4.55 – 4.48 
(m, 4H, H-4’ and H-3’, dia1 + dia2), 4.01-3.86 (m, 6H, CHP and O-CH2-
CH3, dia1 + dia2), 3.75 – 3.60 (m, 4H, H-5’, dia1 + dia2), 1.17 – 1.09 (m,
6H, CH3, dia1 + dia2). 13C NMR (126 MHz, D2O): δ 168.9 (CO, dia1 +
dia2), 155.2 (C-6, dia1 + dia2), 152.4 (C-2, dia1 or dia2), 152.3 (C-2, dia1
or dia2), 148.5 (C-4, dia2), 148.4 (C-4, dia1), 141.2 (C-8, dia1 + dia2),
119.4 (C-5, dia1 + dia2), 89.4 (C-1’, dia1 + dia2), 79.9 (C-4’, dia2), 79.2 
(C-4’, dia1), 73.3 (C-2’, dia1), 73.0 (C-2’, dia2), 71.5 (C-3’, dia1), 71.4 (C-
3’, dia2), 62.6 – 59.9 (m, CHP and O-CH2-CH3, dia1 + dia2), 49.3 – 48.8
(m, C-5’, dia1 + dia2), 15.9 – 15.8 (m, CH3, dia1 + dia2). 31P NMR (202 
MHz, D2O): δ 7.9 (dia1 or dia2), 7.8 (dia1 or dia2). Q-TOF MS E+: m/z 
477.09 (M+H)+. HRMS Q-TOF MS E+: calculated for C14H20N6O8PNa2
[M+H]+ 477.0876; found 477.0876.
5’-Deoxy-5’-N-[(phosphorylacetate)]adenosine (tri sodium salt) (8) 
The title compound was obtained as a white solid (78.9 mg, 77%) from 
compound 17 (219.2 mg, 0.45 mmol) using general procedure B. 
Purification was carried out by reverse phase column chromatography 
with H2O/MeOH (100/0 to 0/100) to afford desired compound as a 
triethylammonium salt. This last was then dissolved in a NaOH solution 
(1M in H2O, 2.1 mL, 10 eq.) and stirred at room temperature for a week 
the solution was adjusted to pH = 5 with an ion exchange resin DOWEX 
50WX2 (H+ form). Freeze drying, followed by reverse phase column 
chromatography with H2O/MeOH (0 to 100) and ion exchange on 
DOWEX 50WX2 (Na+ form) provided the desired mixture of 
diastereomers 8. Rf (iPrOH/NH4OH/H2O, 5/1/4) 0.22. 1H NMR (500 MHz, 
D2O): δ 8.28 (d, 2H, H-8, dia1 + dia2), 8.22 (d, 2H, H-2, dia1 + dia2), 6.09 
– 6.06 (m, 2H, H-1’, dia1 + dia2), H-2’ dia1 + dia2 signal in D2O peak, 
4.53 – 4.48 (m, 2H, H-4’, dia1 + dia2), 4.46 – 4.44 (m, 1H, H-3’, dia1),
4.41 – 4.39 (m, 1H, H-3’, dia2), 3.76 (t, J = 14.0 Hz, 2H, CHP, dia1 + 
dia2), 3.69 – 3.52 (m, 4H, H-5’, dia 1 + dia 2). 13C NMR (126 MHz, D2O):
δ 171.7 – 171.6 (m, CO, dia1 + dia2), 155.4 (C-6, dia1 + dia2), 153.0 (C-
2, dia1), 152.8 (C-2, dia2), 148.5 (C-4, dia1 + dia2), 140.5 (C-8, dia1 or 
dia2), 140.4 (C-8, dia1 or dia2), 119.0 (C-5, dia1 + dia2), 88.8 (C-1’, dia1),
88.6 (C-1’, dia2), 79.8 (C-4’, dia1), 79.5 (C-4’, dia2), 73.4 (C-2’, dia2),
73.2 (C-2’, dia1), 71.4 (C-3’, dia2), 71.2 (C-3’, dia1), 64.2 – 63.1 (m, CHP, 
dia1 + dia2), 50.1 – 49.9 (m, C-5’, dia1 + dia2). 31P NMR (202 MHz,
D2O): δ 5.8 (dia1 + dia2). Q-TOF MS E+: m/z 405.09 (M+H)+. HRMS Q-
TOF MS E+: calculated for C12H18N6O8P [M+H]+ 405.0924; found
405.0921.
9-(2,3-O-isopropylidene--D-ribofuranosyl)-6-(2,5-dimethylpyrrol-1-
yl)purine (18)[16] Compound 18 was obtained from commercially 
available adenosine with 36% yield according previously published 
procedure.[16] Characterization (1H) was in agreement with the literature. 
Rf (Petroleum ether / EtOAc, 7/3) 0.23. 1H NMR (400 MHz, CDCl3): δ 
8.92 (s, 1H, H-2), 8.17 (s, 1H, H-8), 6.00 (s, 2H, CH), 5.98 (d, J = 5.0 Hz, 
1H, H-1’), 5.32 – 5.29 (m, 1H, H-2’), 5.16 (dd, J = 5.9, 1.2 Hz, 1H, H-3’), 
4.59 (s, 1H, H-4’), 4.02 and 3.85 (AB, J = 12.8, 1.8 Hz, 2H, H-5’), 2.21 (s, 
6H, CH3), 1.67 (s, 3H, CH3), 1.40 (s, 3H, CH3). 
9-(5-azido-5-deoxy-2,3-O-isopropylidene--D-ribofuranosyl)-6-(2,5-
dimethylpyrrol-1-yl)purine (19) To a stirred solution of compound 18 
(300 mg, 0.78 mmol) in anhydrous 1.4-dioxane (3 mL) was added 
diphenyl phosphoryl azide (336 µL, 2 eq.) and 1,8-
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diazabicyclo[5.4.0]undec-7-ene (350 µL, 3 eq.) under an argon 
atmosphere. The mixture was stirred overnight at room temperature 
before the addition of sodium azide (253 mg, 5 eq.) and a catalytic 
amount of crown ether (15-crown-5, 1.7 mg, 0.01 eq.). This mixture was 
heated at reflux for 4 h, before filtration and concentration to dryness 
under reduced pressure. Purification by column chromatography with 
Petroleum ether/EtOAc (80/20) afforded compound 19 as a white solid 
(319 mg, quantitative yield). Rf (Petroleum ether/EtOAc, 7/3) 0.73. 1H 
NMR (600 MHz, CDCl3): δ 8.95 (s, 1H, H-2), 8.24 (s, 1H, H-8), 6.23 (d, J 
= 2.5 Hz, 1H, H-1’), 5.99 (s, 2H, 2xCH), 5.48 – 5,47 (m, 1H, H-2’), 5.08 – 
5.07 (m, 1H, H-3’), 4.44 – 4.42 (m, 1H, H-4’), 3.69 – 3.62 (m, 2H, H-5’), 
2.20 (s, 6H, CH3 pyrrole), 1.65 (s, 3H, CH3), 1.41 (s, 3H, CH3). 13C NMR 
(151 MHz, CDCl3): δ 152.9 (C-4), 152.7 (C-2), 150.8 (Cq), 143.9 (C-8), 
130.0 (C-5), 129.4 (C-6), 115.4 (Cq), 109.3 (CH), 90.7 (C1’), 85.2 (C-4’), 
84.1 (C-2’), 81.8 (C-3’), 52.4 (C-5’), 27.4 (CH3), 25.5 (CH3), 13.7 (CH3). 
Q-TOF MS E+: m/z 411.19 (M+H)+. HRMS Q-TOF MS E+: calculated for 
C19H23N8O3 [M+H]+ 411.1893; found 411.1891.
9-(5-amino-5-deoxy-2,3-O-isopropylidene--D-ribofuranosyl)-6-(2,5-
dimethylpyrrol-1-yl)purine (20) Compound 19 (587.5 mg, 1.4 mmol) 
was dissolved in absolute ethanol (7 mL) then Palladium on carbon 10% 
(44 mg, 0.03 eq.) was added and the heterogeneous mixture was stirred 
overnight under a hydrogen atmosphere. After filtration through a pad of 
Celite, the residual mixture was concentrated in vacuum. Purification by 
column chromatography with CH2Cl2/MeOH (90/10) afforded compound 
20 as a white solid (539 mg, 98%). Rf (CH2Cl2/MeOH, 9/1) 0.58. 1H NMR 
(600 MHz, CDCl3): δ 8.93 (s, 1H, H-2), 8.28 (s, 1H, H-8), 6.15 (d, J = 3.3 
Hz, 1H, H-1’), 5.98 (s, 2H, 2xCH), 5.48 – 5.46 (m, 1H, H-2’), 5.07 – 5.06 
(m, 1H, H-3’), 4.33 – 4.31 (m, 1H, H-4’), 3.13 – 3.02 (m, 2H, H-5’), 2.20 (s, 
6H, CH3), 1.65 (s, 3H, CH3), 1.40 (s, 3H, CH3). 13C NMR (151 MHz, 
CDCl3): δ 153.0 (C-4), 152.6 (C-2), 150.7 (Cq), 144.2 (C-8), 129.9 (C-5), 
129.5 (C-6), 115.2 (C), 109.3 (CH), 90.9 (C-1’), 87.1 (C-4’), 83.8 (C-2’), 
81.8 (C-3’), 43.7 (C-5’), 27.4 (CH3), 25.5 (CH3), 13.7 (CH3). Q-TOF MS 
E+: m/z 385.20 (M+H)+. HRMS Q-TOF MS E+: calculated for C19H25N6O3 
[M+H]+ 385.1988; found 385.1986. 
9-(5-deoxy-2,3-O-isopropylidene--D-ribofuranosyl-5-N[(tetraethyl 
(methylene bisphosphonate))]-6-(2,5-dimethylpyrrol-1-yl)- purine 
(21) Compound 20 (260mg, 0.68 mmol), triethyl orthoformiate (135 µL,
1.2 eq.) and diethylphosphite (306 µL, 3.5 eq.) were sealed in a 
microwave reactor under stirring. Microwave irradiations were applied for
2 h at 125°C with a power of 850 Watts. The resulting brown oil was
purified by column chromatography CH2Cl2/MeOH (95/5) to afford the 
(aminomethylene) bisphosphonate 21 as a white solid (157 mg, 34%). Rf 
(CH2Cl2/MeOH, 9/1) 0.72. 1H NMR (500 MHz, CDCl3): δ 9.01 (s, 1H, H-2),
8.33 (s, 1H, H-8), 6.12 (d, J = 3.8 Hz, 1H, H-1’), 5.98 (s, 2H, 2xCH), 5.43 
(dd, J = 6.5, 3.8 Hz, 1H, H-2’), 5.13 (dd, J = 6.5, 3.2 Hz, 1H, H-3’), 4.40 – 
4.38 (m, 1H, H-4’), 4.23 – 4.15 (m, 8H, O-CH2), 3.41 – 3.32 (m, 2H, H-5’ 
and CHP), 3.11 – 3.08 (m, 1H, H-5’), 2.20 (s, 6H, CH3), 1.64 (s, 3H, CH3),
1.39 (s, 3H, CH3), 1.32 – 1.27 (m, 12H, O-CH2-CH3). 13C NMR (101 MHz,
CDCl3): δ 153.2 (C-4), 152.9 (C-2), 150.7 (Cq), 144.0 (C-8), 130.0 (C-5),
129.4 (C-6), 115.1 (Cq), 109.2 (CH), 90.8 (C-1’), 85.7 (C-4’), 83.5 (C-2’),
81.9 (C-3’), 63.3 – 63.0 (m, O-CH2), 56.3 – 53.4 (m, CHP), 51.5 (C-5’), 
27.5 (CH3), 25.6 (CH3), 16.6 (O-CH2-CH3), 13.7 (CH3). 31P NMR (202
MHz, CDCl3): δ 19.5 – 19.0 (m, 2P). Q-TOF MS E+: m/z 671.27 (M+H)+. 
HRMS Q-TOF MS E+: calculated for C28H45N6O9P2 [M+H]+ 671.2723; 
found 671.2720.
5’-Deoxy-5’-N-[(tetraethyl(methylene bisphosphonate))]adenosine 
(22) The title compound was obtained as a white solid (89 mg, 74%) from
compound 21 (146.2 mg, 0.2 mmol) using general procedure A (with a 
ratio of TFA/H2O, 9/1). Purification was achieved by column 
chromatography with CH2Cl2/MeOH (90/10). Rf (CH2Cl2/MeOH, 9/1) 0.22. 
1H NMR (500 MHz, CD3OD): δ 8.32 (s, 1H, H-2), 8.29 (s, 1H, H-8), 5.94 
– 5.93 (m, 1H, H-1’), H-2’ signal in H2O peak, 4.39 – 4.38 (m, 1H, H-3’),
4.24 – 4.14 (m, 9H, O-CH2-CH3 and H-4’), 3.38 – 3.34 (m, 1H, H-5’), 3.06 
– 3.03 (m, 1H, H-5’), 1.33 – 1.27 (m, 12H, CH3). 13C NMR (126 MHz,
CD3OD): δ 157.0 (C-6), 153.6 (C-2), 150.6 (C-4), 142.2 (C-8), 120.9 (C-
5), 90.8 (C-1’), 86.4 (C-4’), 74.6 (C-2’), 72.9 (C-3’), 64.9 – 64.5 (m, O-
CH2-CH3), 52.6 – 52.5 (m, CHP and C-5’), 16.8 – 16.7 (m, CH3). 31P 
NMR (202 MHz, CD3OD): δ 20.3 – 19.2 (m, 2P). Q-TOF MS E+: m/z 
553.19 (M+H)+. HRMS Q-TOF MS E+: calculated for C19H35N6O9P2 
[M+H]+ 553.1941; found, 553.1938. 
5’-Deoxy-5’-N-(methylene bisphosphonate)adenosine (Tetra sodium 
salts) (9) The title compound was obtained as a white solid (79 mg, 
quantitative yield) from compound 22 (82 mg, 0.15 mmol) using general 
procedure B (but with 20 eq. trimethylsilyl bromide). Purification was 
achieved by reverse-phase column chromatography with H2O followed by 
ion exchange on DOWEX 50WX2 (Na+ form). Rf (iPrOH/NH4OH/H2O, 
6/1/3) 0.36. 1H NMR (400 MHz, D2O): δ 8.38 (s, 1H, H-8), 8.36 (s, 1H, H-
2), 6.13 (d, J = 5.7 Hz, 1H, H-1’), H-2’ signal in D2O peak, 4.62 – 4.58 (m, 
1H, H-4’), 4.52 – 4.50 (m, 1H, H-3’), 3.99 – 3.84 (m, 2H, H-5’), 3.62 (t, J = 
17.7 Hz, 1H, CHP). 13C NMR (151 MHz, D2O): δ 154.2 (C-6), 151.6 (C-
2), 147.2 (C-4), 139.22 (C-8), 117.7 (C-5), 87.3 (C-1’), 78.4 (C-4’), 72.1 
(C-2’), 69.9 (C-3’), 53.4 (CHP), 48.3 (C-5’). 31P NMR (162 MHz, D2O): δ 
7.28 (P), 7.07 (P). Q-TOF MS E-: m/z 439.05 (M-H)-. HRMS Q-TOF MS 
E-: calculated for C11H17N6O9P2 [M-H]- 439.0532 found; 439.0536. 
5’-O-[(phosphorylacetate)]adenosine (trisodium salt) (23) This 
compound was obtained according to the procedure describe by 
Debarge et al.[18] Characterizations (1H and MS) were in agreement with 
the literature. 1H NMR (400 MHz, D2O): δ 8.62 (s, 1H, H-8, dia1 or dia2), 
8.60 (s, H-8, 1H, dia1 or dia2), 8.18 (s, 2H, H-2, dia1 + dia2), 6.07 (s, 1H, 
H-1’, dia1 or dia2), 6.06 (s, 1H, H-1’, dia1 or dia2), H-2’ signal in D2O 
peak, 4.53 – 4.45 (m, 2H, H-4’, dia1 or dia2), 4.34 – 4.30 (m, 2H, H-3’,
dia1 or dia2), 3.99 – 3.94 (m, 2H, CHP, dia1 or dia2), 3.90 – 3.61 (m, 4H,
H-5’, dia1 + dia2). HRMS Q-TOF MS E+ calculated for C12H17N5O9P 
[M+H]+ 406.0764 found; 406.0763.
2’-Arabino-fluoro-5’-N-[(bisphosphono)methyl]-2-chloro-2’,5’-
dideoxyadenosine (24) The title compound was synthesized from 
commercially available Clofarabine according to procedure detailed in the 
SI. Rf (iPrOH/NH4OH/H2O, 7/1/2) 0.04. 1H NMR (600 MHz, D2O): δ 8.53 
(s, 1H, H-8), 6.46 (dd, J = 16.1, 4.1 Hz, 1H, H-1'), 5.36– 5.26 (m, 1H, H-
2'), 4.72 – 4.66 (m, 1H, H-3'), 4.41– 4.38 (m, 1H, H-4'), 3.67– 3.51 (m, 2H, 
H-5'), 3.05 (d, J = 10.8 Hz, 4H, N-CH2).13C NMR (151 MHz, D2O) δ 156.4
(C-2), 153.8 (C-6), 149.9 (C-4), 142.0 (C-8), 117.1 (C-5), 94.5 (d, J = 
191.3 Hz, C-2'), 82.2 (d, J = 17.1 Hz, C-1'), 80.1 (C-4'), 75.6 (d, J = 25.4
Hz, C-3'), 57.4 (C-5'), 55.4 (d, J = 137.1 Hz, H2C-N). 31P NMR (400 MHz,
MeOD) δ 13.2. 19F NMR (400 MHz, MeOD) δ -198.4. Q-TOF MS E-: m/z 
489.03 (M-H)-. HRMS Q-TOF MS E-. Calculated for C12H17N6O8FP2Cl [M-
H]- 489.0256; found: 489.0256
Molecular modelling and docking. All compounds were modelled using 
the VegaZZ molecular modelling suite and subjected to energy 
minimization of the potential energy by 500 steps of steepest-descent 
gradient followed by 5, 000 steps of conjugate gradient algorithm (Tripos 
force field and Gasteiger-Marsili partial charges) until convergence with a 
gradient tolerance of 0.001 kcal/mol. Å).[19] Molecular docking was 
achieved with Gold v5.6 (Genetic Optimization for Ligand Docking) from 
the Cambridge Crystallographic Data Centre (CCDC, Software Limited) 
on the crystal structure of CD73 (PDB 4H2I) solved at 2 Å of resolution in 
a closed conformation (crystal form III from Knapp K. et al.[8]). Target 
binding site was defined by a spherical area around the CZ atom of 
Arg395 (as this residue is located in the center of the substrate binding 
site and in contact with phosphonate oxygen’s of APCP) with a radius 10 
Å and scrutiny of cavity. Water molecules from the crystal were 
preserved and allowed for translation / rotation freedoms within a 2 Å 
window. The search of best docking poses was performed by executing 
50 runs of genetic algorithms (search-based optimization technique 
based on Genetics and natural selection) and the ranking of docking 
solutions was computed by the GoldScore fitness function by using the 
complete linkage clustering method from the RMSD matrix of generated 
solutions.[20] The GoldScore scoring function was selected as it has been 
optimized for the prediction of ligand binding positions and takes into 
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account factors such as H-bonding energy, van der Waals energy, metal 
interaction and ligand torsion strain (thus, the score reflects the 
theoretical affinity and is expressed as arbitrary units in GOLD). The 
highest-ranked poses were selected for structural analysis and 
interaction measurements with CD73 amino acids using the PyMol 
Molecular Graphics System (v1.8, Schrödinger, LLC). 
Enzymatic inhibition assays. CD73 activity was evaluated using the 
purified recombinant enzyme as previously described[17] by quantifying 
the inorganic phosphate release upon AMP hydrolysis. Briefly, the 
amount of inorganic phosphate produced was determined by using the 
Green Malachite Phosphate assay kit (Gentaur) and a standard 
phosphate concentration range (0-50 µM) for normalizing raw data. To 
determine the enzymatic inhibition, recombinant CD73 (2 nM, final 
concentration) was incubated in a reaction buffer (Tris 50 mM, pH 7.5, 
NaCl 100 mM, MgCl2 1 mM, CaCl2 1 mM and ZnCl2 5 µM) in the absence 
or in the presence of the indicated compounds at various concentrations 
for 1 minute at room temperature. The reaction was started by addition of 
the substrate, AMP (100 µM) and incubated for 2 minutes at 37°C under 
gentle shaking. Then, reaction was stopped by addition of the Green 
Malachite reagent (containing a strong acid) and inorganic phosphate 
produced was quantified by reading the optical density (OD) at 630 nm 
on a plate reader (Tecan Sunrise). The percentage of enzymatic 
inhibition was calculated by using the following formula: 1 - 
[(ODAMP+inhibitor – ODmin) / (ODmax – ODmin)]. ODmin refers to the 
absorbance without enzymatic reaction (background signal) and ODmax, 
the full reaction in absence of inhibitor. To determine IC50 values of the 
inhibitory compounds, GraphPad Prism was used. 
Cell-based assays. Inhibition of CD73 activity on cells were assessed 
using CD73-positive human breast cancer MDA-MB-231 cells. Cells 
(25,000 per well) were seeded in 96-well plates in 100 µL complete 
media and left to adhere overnight. After 4 washes with 100 µL buffer 
(MgCl2 2 mM, NaCl 120 mM, KCl 5 mM, glucose 10 mM, Hepes 20 mM 
pH 7.4), cells were incubated with 100 µL containing (or not) 200 µM 
AMP and 100 µM inhibitors for 10 minutes. Then, the reaction was 
stopped by incubating the plate on ice, and inorganic phosphate was 
quantified with the Green Malachite Phosphate Assay kit (Gentaur). The 
inhibition activity was calculated as 1- (ODAMP+inhibitor – ODinhibitor) / (ODAMP 
– ODonly cells). Every condition was performed in triplicate and at least
three times.
Potential toxicity of studied compounds to human cells was estimated 
after exposing the same cells (3000 cells in 96 well plates) to 100 µM of 
compounds for 72 h. Then, the relative number of cells was determined 
using the MTT assay. 
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